MedTrace Logo

Spironolactone in Atrial Fibrillation

NCT02673463 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2018-10-11

No results posted yet for this study

Summary

This study aims to assess whether treatment with a drug called spironolactone, which is an aldosterone inhibitor, can improve ability to cope with exertion, quality of life and ability of the heart to relax better in symptomatic patients with atrial fibrillation with preserved pumping capacity.

Conditions

Interventions

DRUG

Spironolactone

25 mg once daily

DRUG

Placebo

Visually identical to spironolactone, once daily

Sponsors & Collaborators

  • University of Birmingham

    lead OTHER

Principal Investigators

  • Gregory YH Lip, MD · University of Birmingham

  • Eduard Shantsila, PhD · University of Birmingham

  • Paulus Kirchhof, PhD · University of Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2018-12-31
Completion
2019-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02673463 on ClinicalTrials.gov